U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Dacomitinib. [Updated 2018 Dec 3].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Dacomitinib

Revised: December 3, 2018.

CASRN: 1110813-31-4



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of dacomitinib during breastfeeding. Because dacomitinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 70 hours, the manufacturer recommends that breastfeeding be discontinued during dacomitinib therapy and for at least 17 days after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Dacomitinib

CAS Registry Number

1110813-31-4

Drug Class

Antineoplastic Agents

Enzyme Inhibitors

Tyrosine Kinase Inhibitors

Lactation

Breast Feeding